id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0262-0004,FDA,FDA-2003-E-0262,Determination of Regulatory Review Period for Purposes of Patent Extension; DERAMAXX,Notice,General Notice,2003-12-03T05:00:00Z,2003,12,2003-12-01T05:00:00Z,,2025-10-23T23:36:46Z,03-29742,0,0,090000648049048b
FDA-2003-E-0262-0003,FDA,FDA-2003-E-0262,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-23T23:30:17Z,,0,0,090000648049048a
FDA-2003-E-0262-0002,FDA,FDA-2003-E-0262,Letter from U S Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-10-06T04:00:00Z,2003,10,,,2025-10-23T23:23:49Z,,0,0,0900006480490489
FDA-2003-E-0262-0001,FDA,FDA-2003-E-0262,Letter from U S Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-06T04:00:00Z,2003,6,,,2025-10-23T23:20:38Z,,0,0,0900006480490456